Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-ranging study of CP-690,550 plus methotrexate in active rheumatoid arthritis with inadequate response to methotrexate
2006-005036-24Phase 2Completed
- Sponsor
- Pfizer
- Start
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tofacitinib in rheumatoid arthritis (RA) (7 arms), sponsored by Pfizer. Primary endpoint: ACR20 responder rate. Started Mar 2007; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2006-005036-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005036-24.